<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462578</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-RELA02-048</org_study_id>
    <secondary_id>2010-022388-37</secondary_id>
    <secondary_id>VZ-MDS-PI-0245</secondary_id>
    <nct_id>NCT01462578</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)</brief_title>
  <acronym>RELAZA2</acronym>
  <official_title>Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of efficacy of azacitidine to prevent a relapse
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of the effectiveness of azacitidine 6 months after start of therapy to prevent a
      hematological relapse in MDS or AML patients with significant residuals or an increase of
      minimal residual disease (MRD) which is defined as:

        -  decrease of CD34 donor chimerism (&lt;80%) after allogeneic related or unrelated HSCT in
           CD34+ or CD117+ MDS or AML or

        -  increase in the AML-specific molecular markers in the quantitative PCR for t(6,9), NPM1+
           AML &gt;1% (ratio to reference gene) after conventional chemotherapy or allogeneic HSCT or

        -  persistence of the (above) MRD level &gt;1% after conventional chemotherapy or allogeneic
           HSCT

        -  tolerance of azacitidine

        -  quality of the response of the MRD (major vs. minor) and the relapse-free survival and
           overall survival 12, 24 and 30 months after starting treatment with azacitidine

        -  modulation of CD34+, NK- and T-cells of MDS and AML patients by azacitidine
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hematological relapse 6 months after start of treatment with azacitidin</measure>
    <time_frame>6 months after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of occurrence or exacerbation of clinical relevant acute or chronic GvHD</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infectious SAEs (rate of SAE)</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of changes of methylation in CD34+ cells</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival and overall survival</measure>
    <time_frame>12, 24 and 30 months after start of treatment</time_frame>
    <description>Relapse-free survival and overall survival 12, 24 and 30 months after start of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Acute Myelocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacytidine injection: 75 mg/m²/d, subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles</description>
    <arm_group_label>Azacytidine</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Screening:

          -  signed informed consent

          -  Age ≥18 years

          -  patients with MDS or AML after conventional chemotherapy or allogeneic HSCT and
             positive molecular marker such as t(6,9), NPM1 pos. or CD34+ or CD117+ in the case of
             an allogeneic HSCT

        Treatment:

          -  MDS or AML without haematological relapse (blasts &lt;5% in the bone marrow), and

          -  decrease of CD34 donor chimerism (&lt;80%) after allogeneic related or unrelated HSCT in
             CD34+ or CD117+ MDS or AML or

          -  increase in the AML-specific molecular marker in the quantitative PCR for t(6,9),
             NPM1+ AML &gt;1% after conventional chemotherapy or allogeneic HSCT or

          -  persistence of the (above) MRD levels &gt;1% (relative to the reference gene) after
             conventional chemotherapy or allogeneic HSCT

          -  leukocytes &gt; 3 Gpt/l and platelets &gt;75 Gpt/l (transfusion independent)

        Exclusion Criteria:

          -  Known history of hypersensitivity to any of the drugs used or their constituents or to
             drugs with similar chemical structure,

          -  Participation of the patient in another clinical trial within the last 4 weeks before
             the inclusion

          -  addiction or other disorders that do not allow the concerned person, to assess the
             nature and scope and possible consequences in the clinical investigation

          -  pregnant or breast feeding women

          -  women of childbearing potential, except women who meet the following criteria:

               -  post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum
                  FSH &gt;40 U/ml)

               -  postoperative (6 weeks after hysterectomy with or without bilateral ovariectomy )

               -  regular and proper use of a contraceptive method with error rate &lt;1% per year
                  (e.g., implants, depot injections, oral contraceptives, intrauterine device, IUD)
                  during study treatment and up to 1 year after completion of therapy

               -  sexual abstinence during study treatment and up to 1 year after completion of
                  therapy

               -  Vasectomy of the partner

          -  Men who do not use one of the following types of effective contraception during study
             treatment and up to 1 year after completion of therapy:

               -  sexual abstinence

               -  State post-vasectomy

               -  Condom

          -  Evidence that the participating person is not expected to comply with the protocol
             (such as lack of cooperation)

          -  Uncontrolled active infection

          -  Severe hepatic impairment (AST and ALT may not exceed three times the normal) or liver
             cirrhosis or malignant liver tumor

          -  Dialysis dependent renal dysfunction

          -  Known severe congestive heart failure, incidence of clinically unstable cardiac or
             pulmonary disease These criteria are not for the screening phase up to a known
             allergic reaction to azacitidine or intolerance to apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, 01307 Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <email>Uwe.Platzbecker@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antje Schubert, Dr.</last_name>
    <email>antje.schubert@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Baldus, Prof. Dr.</last_name>
      <email>claudia.baldus@charite.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Baldus, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz (Küchwald)</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Herbst, Dr. med.</last_name>
      <email>r.herbst@skc.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Hänel, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
      <email>uwe.platzbecker@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wermke, Dr. med.</last_name>
      <email>martin.wermke@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie (Westdeutsches Tumorzentrum)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Noppeney, Dr. med.</last_name>
      <email>richard.noppeney@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Richard Noppeney, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Medizinische Klinik II Hämatologie / Onkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gesine Bug, PD Dr. med.</last_name>
      <email>g.bug@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Gesine Bug, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lübbert, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Lübbert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik, Abt. Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, Prof. Dr.</last_name>
      <email>Alwin.Kraemer@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Tilmann Bochtler, Dr. med.</last_name>
      <email>tilmann.bochtler@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alwin Krämer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München, III. Med. Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Götze, PD Dr. med.</last_name>
      <email>K.Goetze@lrz.tu-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Katharina Götze, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU München, Klinikum Großhadern, Med. Klinik III</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Pastore, Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Stefani Lippl, Dr. med.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karsten Spiekermann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Innere Medizin A - KMT-Zentrum</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <email>stelljes@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org</url>
    <description>Website Study Alliance Leukemia (coordinating study group)</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms benign, malignant and unspecified</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

